1-12002069-A-G
Variant summary
Our verdict is Pathogenic. Variant got 19 ACMG points: 19P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_014874.4(MFN2):c.1126A>G(p.Met376Val) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. M376L) has been classified as Uncertain significance.
Frequency
Consequence
NM_014874.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 19 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MFN2 | NM_014874.4 | c.1126A>G | p.Met376Val | missense_variant | 11/19 | ENST00000235329.10 | NP_055689.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MFN2 | ENST00000235329.10 | c.1126A>G | p.Met376Val | missense_variant | 11/19 | 1 | NM_014874.4 | ENSP00000235329.5 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 33
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
not provided Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Aug 08, 2024 | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis indicates that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 22926664, 22492563, 23381770, 26801520, 24473995, 19889647, 28251916, 30649465, 34721278, 34758253, 37910431, Lagos2021[Abstract], 34255403, 26094742, 22851605, 38549004) - |
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Feb 05, 2021 | This variant was not reported in large, multi-ethnic, general populations (http://gnomad.broadinstitute.org). This variant appears to occur de novo in multiple individuals with clinical features associated with this gene. Assessment of experimental evidence regarding the effect of this variant on protein function is inconclusive. Although there were changes to ER-mitochondrial connectivity and mitochondria-associated ER membranes (MAM) function, this study used patient-derived cells and results could be influenced by factors other than this variant (PMID: 30649465). - |
Charcot-Marie-Tooth disease type 2A2 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | Mar 22, 2022 | Same or different nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000217161). The variant has been observed in multiple (>3) similarly affected unrelated individuals (PMID: 19889647, 22926664, 26801520, 22492563, 22851605, 28251916). Different missense changes at the same codon have been reported to be associated with MFN2 related disorder (PMID:16835246,24957169,16762064). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.794>=0.6, 3CNET: 0.806>=0.75). A missense variant is a common mechanism. It is not observed in the gnomAD v2.1.1 dataset. Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. - |
MFN2-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Oct 18, 2023 | The MFN2 c.1126A>G variant is predicted to result in the amino acid substitution p.Met376Val. This variant was reported in several individuals with autosomal dominant Charcot-Marie-Tooth disease (Casasnovas et al 2010. PubMed ID: 19889647; Vielhaber S et al 2012. PubMed ID: 22926664; Nightingale H et al 2014. PubMed ID: 24473995) including at least one instance of it occurring de novo in a patient (Supp. Table 1 in Bansagi B et al 2017. PubMed ID: 28251916). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. This variant is interpreted as pathogenic. - |
Inborn genetic diseases Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 12, 2019 | The p.M376V variant (also known as c.1126A>G), located in coding exon 9 of the MFN2 gene, results from an A to G substitution at nucleotide position 1126. The methionine at codon 376 is replaced by valine, an amino acid with highly similar properties. This variant has been identified de novo in an individual with MFN2-related neuropathy (Bansagi B et al. Neurology, 2017 Mar;88:1226-1234). This alteration has also been identified in multiple individuals with phenotype consistent with MFN2-related neuropathy (Casasnovas C et al. J. Med. Genet., 2010 Apr;47:249-56; Vielhaber S et al. Acta Neuropathol., 2013 Feb;125:245-56; Nightingale H et al. BMJ, 2014 Jan;348:g459). In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Hereditary motor and sensory neuropathy with optic atrophy Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Genomics England Pilot Project, Genomics England | - | - - |
Charcot-Marie-Tooth disease type 2 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 23, 2023 | ClinVar contains an entry for this variant (Variation ID: 217161). This sequence change replaces methionine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 376 of the MFN2 protein (p.Met376Val). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with autosomal dominant Charcot-Marie-Tooth disease (PMID: 19889647, 22492563, 22851605, 22926664, 24473995, 26801520, 28251916). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MFN2 protein function. This variant disrupts the p.Met376 amino acid residue in MFN2. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 24957169). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at